Group 1 - Tevogen Bio Holdings Inc. will have its CEO, Dr. Ryan Saadi, participate in BioNJ's Fifteenth Annual Bio Partnering Conference, focusing on strategies for adapting to market volatility [1][2] - The conference aims to foster strategic partnerships and drive funding within the biopharmaceutical industry, ultimately advancing medical innovation [2][3] - Dr. Saadi emphasized the importance of addressing market volatility and its impact on patient outcomes, aligning with Tevogen Bio's mission to enhance accessibility to lifesaving treatments [3] Group 2 - The conference will feature a dynamic agenda including 1:1 partnering sessions, company pitch presentations, and extensive networking opportunities designed for growth and collaboration [3] - BioNJ President and CEO Debbie Hart expressed excitement for the panel discussion, highlighting the potential for attendees to gain actionable insights [3]

Core Insights - Tevogen Bio Holdings Inc. will participate in BioNJ's Fifteenth Annual Bio Partnering Conference, focusing on strategies for adapting to market volatility [1][2] - The conference aims to foster strategic partnerships and drive funding within the biopharmaceutical industry, ultimately advancing medical innovation [2][3] Company Participation - CEO Dr. Ryan Saadi will be featured in a panel discussion titled "Paths to Liquidity: Strategies for Adapting to a Volatile Market" [1] - The panel will include notable industry figures from J.P. Morgan Private Bank, RSM US, and Cantor Fitzgerald, indicating a strong representation of financial expertise [1] Industry Context - The biotechnology industry is currently facing market volatility, which could impact patient outcomes, highlighting the importance of discussions at the conference [3] - The conference will include various activities such as 1:1 partnering sessions, company pitch presentations, and extensive networking opportunities, designed to support growth and collaboration in the industry [3]